Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (Fv-IgG) (CAT#: BSDG-151)
Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-doxorubicin IgG with similar domains from an anti-EGFR antibody via short peptide linkers, or vice versa. This BsAb can be used in pretargeting system and deliver toxin to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
There are currently no customer reviews or questions for Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (Fv-IgG) (BSDG-151). Click the button below to contact us or submit your feedback about this product.